Active, not recruitingPhase 1NCT04903080
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
Studying Ependymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Meenakshi Hegde, MDBaylor College of Medicine
- Intervention
- HER2 Specific CAR T Cell(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 1-22 years · All sexes
- Timeline
- 2022 – 2043
Study locations (13)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Pittsburgh Children's Hospital of UPMC, Pittsburgh, Pennsylvania, United States
- Texas Children's Cancer Center, Houston, Texas, United States
- The Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
Texas Children's Cancer Center · Baylor College of Medicine · National Cancer Institute (NCI) · American Lebanese Syrian Associated Charities · Pediatric Brain Tumor Consortium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04903080 on ClinicalTrials.govOther trials for Ependymoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04743661131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaPediatric Brain Tumor Consortium
- RECRUITINGPHASE1NCT05106296Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerTheodore S. Johnson
- RECRUITINGNCT05151718Multiomic Approach to Radioresistance of Ependymomas in Children and AdolescentsInstitut Claudius Regaud
- ACTIVE NOT RECRUITINGPHASE1NCT04661384Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or MedulloblastomaCity of Hope Medical Center
- ACTIVE NOT RECRUITINGPHASE1NCT02774421Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent EpendymomaUniversity of Colorado, Denver
- RECRUITINGPHASE2, PHASE3NCT02265770An International Clinical Program for the Diagnosis and Treatment of Children With EpendymomaCentre Leon Berard
- ACTIVE NOT RECRUITINGPHASE2NCT02125786A Trial of Surgery and Fractionated Re-Irradiation for Recurrent EpendymomaSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGNCT00683319Observing Young Patients With Ependymoma Undergoing Standard Combination ChemotherapyChildren's Cancer and Leukaemia Group